MedTrace Logo

Varenicline Treatment of Alcohol Dependence in Smokers

NCT01553136 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2020-03-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether varenicline is effective in the treatment of alcohol dependence in smokers.

Conditions

  • Alcoholism
  • Alcohol Abuse
  • Smoking
  • Alcohol Drinking

Interventions

DRUG

Varenicline

0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day

Sponsors & Collaborators

  • Columbia University

    collaborator OTHER

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Stephanie O'Malley, PhD · Yale University

  • Allen Zweben, PhD · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01553136 on ClinicalTrials.gov